B1 kinin receptor does not contribute to vascular tone or tissue plasminogen activator release in the peripheral circulation of patients with heart failure

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 25, Issue 4, 2005, Pages 772-777

  Cruden, Nicholas L M ^a   Tse, George H ^a   Fox, Keith A A ^a   Ludlam, Christopher A ^a   Megson, Ian ^a   Newby, David E ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

ACE inhibitors; Bradykinin; Heart failure; Plasminogen activators; Receptors

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; BRADYKININ B1 RECEPTOR; BRADYKININ B1 RECEPTOR AGONIST; BRADYKININ B1 RECEPTOR ANTAGONIST; BRADYKININ DERIVATIVE; CALCIUM ANTAGONIST; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; NITRATE; NORADRENALIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD FLOW; BLOOD SAMPLING; BLOOD VESSEL TONE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG MECHANISM; FEMALE; HEART FAILURE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; VASOCONSTRICTION; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY;

ADOLESCENT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CROSS-OVER STUDIES; ENALAPRIL; FEMALE; FIBRINOLYSIS; FOREARM; HEART FAILURE, CONGESTIVE; HUMANS; KALLIDIN; LOSARTAN; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREGNANCY; RECEPTOR, BRADYKININ B1; REGIONAL BLOOD FLOW; TISSUE PLASMINOGEN ACTIVATOR; UMBILICAL VEINS; VASOCONSTRICTION;

EID: 16244391171     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000157157.78822.25     Document Type: Article

References (29)

1. Cruden NL, Witherow FN, Webb DJ, Fox KA, Newby DE. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Arterioscler Thromb Vasc Biol. 2004;24:1043-1048.
2. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med. 1998;339:1285-1292.
3. Witherow FN, Dawson P, Ludlam CA, Fox KA, Newby DE. Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy. J Am Coll Cardiol. 2002;40:961-966.
4. Pretorius M, Rosenbaum D, Vaughan DE, Brown NJ. Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin. Circulation. 2003;107:579-585.
5. 2 receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation. 2000;102:2190-2196.
6. 1 receptor agonist in a non-human primate model: haemodynamic and proinflammatory effects. Br J Pharmacol. 2001;132:327-335.
7. 1-receptor expression after myocardial infarction. Br J Pharmacol. 2000;129:1537-1538.
8. 1 receptors and the cardiovascular system: regulation of expression and function. Cardiovasc Res. 2000;48:194-210.
9. 1-receptors in normotensive rats and mice under chronic angiotensin-converting enzyme inhibitor treatment. Circulation. 2002;105:627-632.
10. 2 receptor stimulation. Circulation. 2000;101:1848-1853.
11. 1 receptors for kinins. J Pharmacol Exp Ther. 1991;259:997-1003.
12. 2 receptors of vasodepressor responses to intravenously administered kinins in anaesthetized dogs. Br J Pharmacol. 1993;110:71-76.
13. Raidoo DM, Ramsaroop R, Naidoo S, Muller-Esterl W, Bhoola KD. Kinin receptors in human vascular tissue: their role in atheromatous disease. Immunopharmacology. 1997;36:153-160.
14. 9-bradykinin in human coronary arteries. Br J Pharmacol. 1995;116:3083-3085.
15. 1 receptors for kinins. Pharmacol Rev. 1998;50:357-386.
16. Witherow FN, Helmy A, Webb DJ, Fox KA, Newby DE. Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Circulation. 2001;104: 2177-2181.
17. 1 receptors in allergic airway inflammation. J Immunol. 2002;169:2054-2060.
18. Gobeil F, Pheng LH, Badini I, Nguyen-Le XK, Pizard A, Rizzi A, Blouin D, Regoli D. Receptors for kinins in the human isolated umbilical vein. Br J Pharmacol. 1996;118:289-294.
19. Newby DE, Masumori S, Johnston NR, Boon NA, Webb DJ. Endogenous angiotensin II contributes to basal peripheral vascular tone in sodium deplete but not sodium replete man. Cardiovasc Res. 1997;36:268-275.
20. 1 receptors in human umbilical vein: pharmacological evidence of up-regulation, and induction by interleukin-1 beta. Eur J Pharmacol. 1998;358:221-227.
21. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987; 316:1429-1435.
22. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-1587.
23. Newby DE, Wright RA, Ludlam CA, Fox KA, Boon NA, Webb DJ. An in vivo model for the assessment of acute fibrinolytic capacity of the endothelium. Thromb Haemost. 1997;78:1242-1248.
24. Chandler WL, Alessi MC, Aillaud MF, Henderson P, Vague P, Juhan-Vague I. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation. 1997;96:761-768.
25. Brown NJ, Kumar S, Painter CA, Vaughan DE. ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time. Hypertension. 2002;40:859-865.
26. 1 bradykinin receptor in normotension and hypertension. Circ Res. 2001;88:275-281.
27. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236-241.
28. 1 receptor expression and leukocyte trafficking across mouse mesenteric postcapillary venules. J Exp Med. 2000;192:367-380.
29. 1 receptor for therapeutic neovascularization. Circulation. 2002;105:360-625.